Cheap supplies of HIV-prevention jab for poorer countries hailed as ‘genuine chance to end’ global epidemic
Lenacapavir described as ‘next best thing’ to an HIV vaccine will cost $40 a year for each patient in 120 countries from 2027, funders say
Cheap supplies of a groundbreaking twice-yearly HIV prevention jab will be available in many poorer countries within two years, funders have promised.
Lenacapavir will cost $40 (£30) a patient a year in 120 low- and middle-income countries from 2027, under two agreements with generic drug manufacturers announced this week.